Healthcare professional educational plan for pre-filled syringe 43. Nilotinib (Tasigna) - QT prolongation - Patient / HCPs - Myelosuppression educational materials. - Cardiovascular events - Significant bleeding - Severe infections - Hepatotoxicity - Pancreatitis, lipase and amylase elevations - Fluid retention - glucose increased - Blood cholesterol increased - Use in patients with hepatic impairment - Interaction with strong CYP3A4 inhibitors 44. Bosentan Monohydrate - Teratogenicity - Controlled - Hepatotoxicity distribution system (Bosentan) - Decrease in haemoglobin concentration HCP and Patient - Decrease in sperm count educational materials. 45. Agomelatine (Valdoxan®) - liver Function (hepatotoxicity) - patient booklet -Doctor guide 46. Menotrophin - Ovarian Hyperstimulation Syndrome (OHSS) - Doctor guide 47. Pioglitazone/glimepride(Duetact®) - congestive heart failure - prescriber guide - not recommended in patients with symptomatic failure - d NYHA Class III or IV heart failure is contraindicated 48. Misoprestol (Misodel®) - uterine tachysystole - presciber guide 49. Acitretin (Neotigasone®) - Risk of malformation and formation of a compound (etretinate), - pregnancy prevention which may be harmful to an unborn child program (HCP , patient) educational material 50. Bendamustine (Bendavival®) - Myelosuppression - physician guide - Infections - pharmacist guide - Anaphylaxis and Infusion Reactions - Tumor Lysis Syndrome - Skin Reactions - Hepatotoxicity
Healthcare professional educational plan for pre-filled syringe 43. Nilotinib (Tasigna) - QT prolongation - Myelosuppression - Cardiovascular events - Significant bleeding - Severe infections - Hepatotoxicity - Pancreatitis, lipase and amylase elevations - Fluid retention - glucose increased - Blood cholesterol increased - Use in patients with hepatic impairment - Interaction with strong CYP3A4 inhibitors - Patient / HCPs educational materials. 44. Bosentan Monohydrate (Bosentan) - Teratogenicity - Hepatotoxicity - Decrease in haemoglobin concentration - Decrease in sperm count - Controlled distribution system HCP and Patient educational materials. 45. Agomelatine (Valdoxan®) - liver Function (hepatotoxicity) - patient booklet -Doctor guide 46. Menotrophin - Ovarian Hyperstimulation Syndrome (OHSS) - Doctor guide 47. Pioglitazone/glimepride(Duetact®) - congestive heart failure - not recommended in patients with symptomatic failure - d NYHA Class III or IV heart failure is contraindicated - prescriber guide 48. Misoprestol (Misodel®) - uterine tachysystole - presciber guide 49. Acitretin (Neotigasone®) - Risk of malformation and formation of a compound (etretinate), which may be harmful to an unborn child - pregnancy prevention program (HCP , patient) educational material 50. Bendamustine (Bendavival®) - Myelosuppression - Infections - Anaphylaxis and Infusion Reactions - Tumor Lysis Syndrome - Skin Reactions - Hepatotoxicity - physician guide - pharmacist guide
Risk%20minimization%20activity.docx